The Safety, Tolerability, and Effects on the Systemic Inflammatory Response and Renal Function of the Human Chorionic Gonadotropin Hormone-Derivative EA-230 Following On-Pump Cardiac Surgery (The EASI Study): Protocol for a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study.
| Title: | The Safety, Tolerability, and Effects on the Systemic Inflammatory Response and Renal Function of the Human Chorionic Gonadotropin Hormone-Derivative EA-230 Following On-Pump Cardiac Surgery (The EASI Study): Protocol for a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study. |
|---|---|
| Authors: | van Groenendael R; Department of Intensive Care Medicine, Radboud University Medical Center, Nijmegen, Netherlands.; Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, Netherlands.; Department of Anesthesiology, Pain and Palliative Medicine, Radboud University Medical Center, Nijmegen, Netherlands.; Beunders R; Department of Intensive Care Medicine, Radboud University Medical Center, Nijmegen, Netherlands.; Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, Netherlands.; Hofland J; Department of Anesthesiology, Pain and Palliative Medicine, Radboud University Medical Center, Nijmegen, Netherlands.; Morshuis WJ; Department of Cardiac Surgery, Radboud University Medical Center, Nijmegen, Netherlands.; Kox M; Department of Intensive Care Medicine, Radboud University Medical Center, Nijmegen, Netherlands.; Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, Netherlands.; van Eijk LT; Department of Anesthesiology, Pain and Palliative Medicine, Radboud University Medical Center, Nijmegen, Netherlands.; Pickkers P; Department of Intensive Care Medicine, Radboud University Medical Center, Nijmegen, Netherlands.; Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, Netherlands. |
| Source: | JMIR research protocols [JMIR Res Protoc] 2019 Feb 06; Vol. 8 (2), pp. e11441. Date of Electronic Publication: 2019 Feb 06. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: JMIR Publications Country of Publication: Canada NLM ID: 101599504 Publication Model: Electronic Cited Medium: Print ISSN: 1929-0748 (Print) Linking ISSN: 19290748 NLM ISO Abbreviation: JMIR Res Protoc Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Original Publication: Toronto : JMIR Publications |
| Abstract: | Background: The cardiac surgery-induced systemic inflammatory response may induce postoperative hemodynamic instability and impairment of renal function. EA-230, a linear tetrapeptide (A-Q-G-V), is derived from the beta chain of the human chorionic gonadotropin pregnancy hormone. It has shown immunomodulatory and renoprotective effects in several animal models of systemic inflammation. In phase 1 and phase 2a studies, these immunomodulatory effects were confirmed during human experimental endotoxemia, and EA-230 was found to have an excellent safety profile.; Objective: The objective of this first in-patient study is to test the safety and tolerability as well as the immunomodulatory and renoprotective effects of EA-230 in a proof-of-principle design in patients with systemic inflammation following on-pump cardiac surgery.; Methods: We describe a prospective, randomized, double-blind, placebo-controlled study in which 180 elective patients undergoing on-pump coronary artery bypass grafting, with or without concomitant valve surgery, are enrolled. Patients will be randomized in a 1:1 ratio and will receive either EA-230 (90 mg/kg/hour) or a placebo. These will be infused at the start of the surgical procedure until the end of the use of the cardiopulmonary bypass. The primary focus of this first-in-patient study will be on safety and tolerability of EA-230. The primary efficacy end point is the modulation of the inflammatory response by EA-230 quantified as the change in interleukin-6 plasma concentrations after surgery. The key secondary end point is the effect of EA-230 on renal function. The study will be conducted in 2 parts to enable an interim safety analysis by an independent data monitoring committee at a sample size of 60. An adaptive design is used to reassess statistical power halfway through the study.; Results: This study has been approved by the independent competent authority and ethics committee and will be conducted in accordance with the ethical principles of the Declaration of Helsinki, guidelines of Good Clinical Practice, and European Directive 2001/20/CE regarding the conduct of clinical trials. Results of this study will be submitted for publication in a peer-reviewed scientific journal. Enrollment of this study commenced in July 2016, and results are expected at the end of 2018.; Conclusions: This adaptive phase 2 clinical study is designed to test the safety and tolerability of EA-230 in patients undergoing cardiac surgery. In addition, efficacy end points focused on the effect of the systemic inflammatory response and renal function are investigated.; Trial Registration: ClinicalTrials.gov NCT03145220; https://clinicaltrials.gov/ct2/show/NCT03145220 (Archived by WebCite at http://www.webcitation.org/74JPh8GNN).; International Registered Report Identifier (irrid): DERR1-10.2196/11441.; (©Roger van Groenendael, Remi Beunders, Jan Hofland, Wim J Morshuis, Matthijs Kox, Lucas T van Eijk, Peter Pickkers. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 06.02.2019.) |
| References: | Kidney Int Suppl (2011). 2012 Mar;2(1):8-12. (PMID: 25018916); Br J Clin Pharmacol. 2019 Jul;85(7):1572-1584. (PMID: 30924163); Pediatr Crit Care Med. 2010 Mar;11(2):234-8. (PMID: 19794327); Intensive Care Med. 2008 Sep;34(9):1654-61. (PMID: 18504549); Hum Immunol. 2002 Jan;63(1):1-7. (PMID: 11924526); Intensive Care Med. 2015 Aug;41(8):1411-23. (PMID: 26162677); Crit Care. 2016 Jul 04;20(1):187. (PMID: 27373799); Chest. 1997 Sep;112(3):676-92. (PMID: 9315800); Ann Thorac Surg. 2017 Dec;104(6):2072-2079. (PMID: 28821332); N Engl J Med. 2016 Jul 7;375(1):65-74. (PMID: 27406349); Int J Dermatol. 2003 Jul;42(7):518-20. (PMID: 12839599); PLoS One. 2015 Jan 24;10(1):e0115709. (PMID: 25617900); J Cardiothorac Vasc Anesth. 2013 Oct;27(5):983-1033. (PMID: 23276596); Virulence. 2014 Jan 1;5(1):20-6. (PMID: 24280933); Eur J Cardiothorac Surg. 2012 Apr;41(4):734-44; discussion 744-5. (PMID: 22378855); Circulation. 2006 Jul 4;114(1 Suppl):I409-13. (PMID: 16820609); JAMA. 2005 Dec 7;294(21):2751-7. (PMID: 16333011); Int J Surg. 2005;3(2):129-40. (PMID: 17462274); Clin J Am Soc Nephrol. 2015 Mar 6;10(3):500-14. (PMID: 25376763); Clin Exp Immunol. 2010 Jun;160(3):466-78. (PMID: 20345979); J Infect Dis. 2010 Apr 1;201(7):1072-80. (PMID: 20170375); J Am Soc Nephrol. 2016 Feb;27(2):371-9. (PMID: 26561643); Crit Care Med. 2006 Feb;34(2):344-53. (PMID: 16424713); PLoS One. 2012;7(9):e45738. (PMID: 23029213); Clin Kidney J. 2016 Oct;9(5):682-99. (PMID: 27679715); Br J Clin Pharmacol. 2019 Jul;85(7):1559-1571. (PMID: 30919998); Endocr Metab Immune Disord Drug Targets. 2011 Mar;11(1):32-53. (PMID: 21352093); Biom J. 2009 Apr;51(2):348-57. (PMID: 19358221); Rheumatology (Oxford). 2011 Nov;50(11):1955-68. (PMID: 21890617); Lancet. 2015 Sep 26;386(10000):1243-1253. (PMID: 26460660); Am J Cardiol. 2014 Jan 1;113(1):70-5. (PMID: 24176074); BMJ. 2013 Jan 08;346:e7586. (PMID: 23303884); Clin J Am Soc Nephrol. 2012 Dec;7(12):2073-80. (PMID: 22879432); Chest. 1992 Jun;101(6):1644-55. (PMID: 1303622); Crit Care. 2004 Aug;8(4):R204-12. (PMID: 15312219); Nephrol Dial Transplant. 2009 Sep;24(9):2701-8. (PMID: 19633318); Cytokine. 2009 Feb;45(2):92-8. (PMID: 19128984); Biometrics. 1979 Sep;35(3):549-56. (PMID: 497341); Crit Care. 2005;9(6):R790-7. (PMID: 16356228); J Cardiothorac Vasc Anesth. 2009 Apr;23(2):223-31. (PMID: 18930659); J Am Soc Nephrol. 2015 Dec;26(12):3123-32. (PMID: 25855775); Crit Care Med. 2001 Aug;29(8):1544-50. (PMID: 11505124); J Am Soc Nephrol. 1995 Aug;6(2):257-63. (PMID: 7579093); Immunol Rev. 2011 May;241(1):20-38. (PMID: 21488887); Pediatr Nephrol. 2007 Oct;22(10):1655-8. (PMID: 17665221); JAMA. 2012 Nov 7;308(17):1761-7. (PMID: 23117776); Shock. 2009 Mar;31(3):285-91. (PMID: 18654091); Crit Care Med. 2011 Jan;39(1):126-34. (PMID: 20890188) |
| Contributed Indexing: | Keywords: EA-230; cardiac surgery; clinical trials, phase II as topic; immunomodulation; inflammation; kidney/therapy; pregnancy; safety |
| Molecular Sequence: | ClinicalTrials.gov NCT03145220 |
| Entry Date(s): | Date Created: 20190207 Latest Revision: 20230502 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC6381408 |
| DOI: | 10.2196/11441 |
| PMID: | 30724734 |
| Database: | MEDLINE |
Journal Article